Establishment of a TRPV2 knockout human embryonic stem cell line (WAe009-A-1Y) using episomal vector-based CRISPR/Cas9
Summary
We established a TRPV2-knockout human embryonic stem cell line (WAe009-A-1Y) using a non-integrating episomal CRISPR/Cas9 system. This cell line exhibits an 8-nucleotide frameshift deletion in TRPV2 exon 2, confirmed pluripotency (97.6 % SSEA4+ cells, trilineage differentiation), and a normal female karyotype (46, XX) at passage 30. TRPV2 ablation was validated in differentiated cardiomyocytes, showing >90 % mRNA reduction and absent protein expression. No off-target edits or mycoplasma contamination were detected. This cell resource (STR-authenticated, off-target-free) provides a robust in vitro model to study the biological function of TRPV2 in cardiac mechanotransduction and disease. Copyright © 2025 The Authors. Published by Elsevier B.V. All rights reserved.
| Authors | Bai R, Zhang S, Gu X, You Y, Liu X |
|---|---|
| Journal | Stem cell research |
| Publication Date | 2025 May 30;87:103744 |
| PubMed | 40483902 |
| DOI | 10.1016/j.scr.2025.103744 |